SynthesisFrontiers in medicine2025
Evaluation of the NG-Test Carba 5 for the clinical detection of carbapenemase-producing gram-negative bacteria.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Evaluation of a Novel In Vitro Diagnostic Immunoassay for the Rapid Qualitative Detection of KPC, NDM, OXA-48-like, IMP and VIM Carbapenemases.Diagnostics (Basel, Switzerland) · 2026Article
- Evaluation of the NG-Test CARBA 5 for Rapid Detection of Carbapenemases in Clinical Isolates ofAntibiotics (Basel, Switzerland) · 2025Article
- Comparison of Two Lateral Flow Immunochromatographic Assays for Rapid Detection of KPC, NDM, IMP, VIM and OXA-48 Carbapenemases in Gram-Negatives.Microorganisms · 2025Article
- Analysis of Carbapenem-Resistant Enterobacterales Resistance in a Hospital in Kunming Over the Past Two Years.Infection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Currently, the spread and prevalence of carbapenem-resistant gram-negative bacteria cause a worldwide health problem, significantly affecting patients' prognosis. Therefore, reliable detection of carbapenemases is crucial for managing and controlling infections. Numerous investigations have shown that the innovative immunochromatographic assay NG-Test Carba 5 has great sensitivity and specificity for carbapenemase typing. This meta-analysis aimed to comprehensively assess the efficacy of the NG-Test Carba 5 in the clinical detection of carbapenemase-producing gram-negative bacteria. Methods: Previously published articles were systematically reviewed, relevant data were extracted, and the results were pooled and analyzed using Meta-DiSk 1.4 and Stata 12.0 software. Results: The sensitivity, specificity, positive LR value, and negative LR value for the identification of carbapenemase-type KPC, NDM, VIM, IMP, and OXA-48-like by immunochromatographic NG-Test Carba 5 using PCR as gold standard were 0.97 [95% CI (0.97, 0.98)], 0.99 [95% CI (0.99, 1.00)], 65.38 [95% CI (36.73, 116.39)], and 0.03 [95% CI (0.02, 0.05)], respectively, and the combined diagnostic odds ratio was 2,734.42 [95% CI (1,464.05, 5,107.12)]. The AUC of the SROC curve was 0.9976. Conclusion: In summary, the NG-Test Carba 5 is a clinical test that can identify and quickly detect five major carbapenemases, thus offering valuable insights for clinical decision-making and infection control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.